由icaritin衍生物IC2诱导的脂质液滴形成促进了癌症治疗的组合策略
Guosheng Wu1, Liang Ying1, Qian Zhang1
1MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Chinese medicine
|December 26, 2024
概括
准脂质滴滴形成可以增强癌症治疗. 抑制脂质液滴与IC2一起,一种醇-CoA脱酶1 (SCD1) 抑制剂,通过阻止癌细胞适应治疗来增强抗瘤效应.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 生物化学 生物化学
背景情况:
- 脂质代谢对癌症的进展至关重要,脂质滴 (LDs) 提供了对脂质毒性的保护.
- 来自icaritin的IC2抑制了醇-CoA脱酶1 (SCD1),破坏了脂质代谢并抑制了癌细胞的增殖.
- IC2对细胞内LDs的影响以及针对组合癌症治疗的LD形成的潜力尚未被探索.
研究的目的:
- 研究IC2对癌细胞内细胞内LD形成的影响.
- 探索IC2影响LD和线粒体功能的机制.
- 评估将IC2与LD形成抑制剂结合用于增强抗瘤治疗的潜力.
主要方法:
- 使用显微镜和染色 (Oil Red O, BODIPY) 可视化和量化LD形成.
- 转录分析,实时PCR和免疫阻塞评估了IC2诱导的细胞反应.
- 线粒体功能,脂质来源以及抑制二甲基甘酸转移酶1 (DGAT1) 对IC2抗瘤作用的影响在体外和体内都得到了评估.
主要成果:
- 在癌细胞中,IC2治疗诱导了LD的形成,独立于细胞外脂质或新脂肪酸合成.
- IC2 干扰了线粒体功能,导致ATP 生产受损,并增加了LDs中的脂质积累.
- 将IC2与DGAT1抑制剂相结合,增强了抗增殖和促细胞衰竭的效果,在异种移植模型中减少了瘤生长.
结论:
- LD形成作为对IC2抗瘤作用的补偿机制,危及疗效.
- 将IC2与LD形成抑制剂相结合,显著增强了抗癌活性.
- 这种组合策略对其他调节脂质代谢的抗癌药物具有前景.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:34Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
01:27Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397